Malaria control faces challenges from drug resistance and mosquito adaptation

Malaria control efforts in Africa are facing significant setbacks due to evolving biological threats. In Ethiopia, over 10 million cases were reported in 2024, marking a seven-year high. Research led by the Ethiopian Public Health Institute and the University of North Carolina at Chapel Hill indicates that parasites are developing genetic mutations that allow them to evade both artemisinin-based drug treatments and HRP2-based rapid diagnostic tests. This dual resistance creates a cycle where infections go undetected and treatments fail, allowing resistant strains to proliferate.

To combat rising insecticide resistance and mosquito adaptation, scientists are exploring next-generation control methods. In Johannesburg, the National Institute for Communicable Diseases and the Wits University Research Institute for Malaria are convening an international workshop to develop genetic-based mosquito control. This includes advancing the sterile insect technique (SIT), which involves releasing sterilized male mosquitoes to prevent reproduction, and exploring gene drive technology. Unlike SIT, gene drive technology is designed to spread specific genetic changes through nearly all offspring in a wild population, offering a self-sustaining method to reduce mosquito numbers.